Literature DB >> 34778767

Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies.

Xi Wang1, Yuanxun Wang2, Xuemin Li1, Zhenyang Yu1, Chun Song3, Yunfei Du1.   

Abstract

The nitrile group is an important functional group widely found in both pharmaceutical agents and natural products. More than 30 nitrile-containing pharmaceuticals have been approved by the FDA for the management of a broad range of clinical conditions in the last few decades. Incorporation of a nitrile group into lead compounds has gradually become a promising strategy in rational drug design as it can bring additional benefits including enhanced binding affinity to the target, improved pharmacokinetic profile of parent drugs, and reduced drug resistance. This paper reviews the existing drugs with a nitrile moiety that have been approved or in clinical trials, involving their targets, molecular mechanism of pharmacology and SAR studies, and classifies them into different categories based on their clinical usages. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34778767      PMCID: PMC8528211          DOI: 10.1039/d1md00131k

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  160 in total

1.  The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.

Authors:  Ken Okamoto; Koji Matsumoto; Russ Hille; Bryan T Eger; Emil F Pai; Takeshi Nishino
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

Review 2.  The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes.

Authors:  Anca Pantea Stoian; Alexandros Sachinidis; Roxana Adriana Stoica; Dragana Nikolic; Angelo Maria Patti; Ali A Rizvi
Journal:  Metabolism       Date:  2020-06-15       Impact factor: 8.694

3.  Discovery of sulfonyl hydrazone derivative as a new selective PDE4A and PDE4D inhibitor by lead-optimization approach on the prototype LASSBio-448: In vitro and in vivo preclinical studies.

Authors:  Isabelle Karine da Costa Nunes; Everton Tenório de Souza; Italo Rossi Roseno Martins; Gisele Barbosa; Manoel Oliveira de Moraes Junior; Millena de Melo Medeiros; Sheyla Welma Duarte Silva; Tatiane Luciano Balliano; Bagnólia Araújo da Silva; Patrícia Machado Rodrigues Silva; Vinicius de Frias Carvalho; Marco Aurélio Martins; Lidia Moreira Lima
Journal:  Eur J Med Chem       Date:  2020-07-18       Impact factor: 6.514

4.  Management of Gout.

Authors:  Paul G Shekelle; Sydne J Newberry
Journal:  Ann Intern Med       Date:  2017-06-06       Impact factor: 25.391

5.  Vitamin B12 Inhibits Tau Fibrillization via Binding to Cysteine Residues of Tau.

Authors:  Saharnaz Rafiee; Kazem Asadollahi; Gholamhossein Riazi; Shahin Ahmadian; Ali Akbar Saboury
Journal:  ACS Chem Neurosci       Date:  2017-09-06       Impact factor: 4.418

6.  Discovery and biological evaluation of darolutamide derivatives as inhibitors and down-regulators of wild-type AR and the mutants.

Authors:  Jiang Yu; Peiting Zhou; Mingxing Hu; Liuqing Yang; Guoyi Yan; Ruixue Xu; Yufang Deng; Xinghai Li; Yuanwei Chen
Journal:  Eur J Med Chem       Date:  2019-08-10       Impact factor: 6.514

Review 7.  Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.

Authors:  Prithviraj Bose; Howard Ozer
Journal:  Expert Opin Investig Drugs       Date:  2009-11       Impact factor: 6.206

8.  FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.

Authors:  Diana Bradford; Erin Larkins; Sirisha L Mushti; Lisa Rodriguez; Amy M Skinner; Whitney S Helms; Lauren S L Price; Jeanne Fourie Zirkelbach; Yangbing Li; Jiang Liu; Rosane Charlab; Francisca Reyes Turcu; Dun Liang; Soma Ghosh; Donna Roscoe; Reena Philip; Autumn Zack-Taylor; Shenghui Tang; Paul G Kluetz; Julia A Beaver; Richard Pazdur; Marc R Theoret; Harpreet Singh
Journal:  Clin Cancer Res       Date:  2020-11-25       Impact factor: 12.531

9.  P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.

Authors:  Ryohei Katayama; Takuya Sakashita; Noriko Yanagitani; Hironori Ninomiya; Atsushi Horiike; Luc Friboulet; Justin F Gainor; Noriko Motoi; Akito Dobashi; Seiji Sakata; Yuichi Tambo; Satoru Kitazono; Shigeo Sato; Sumie Koike; A John Iafrate; Mari Mino-Kenudson; Yuichi Ishikawa; Alice T Shaw; Jeffrey A Engelman; Kengo Takeuchi; Makoto Nishio; Naoya Fujita
Journal:  EBioMedicine       Date:  2015-12-12       Impact factor: 8.143

Review 10.  The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19.

Authors:  Bakiye Goker Bagca; Cigir Biray Avci
Journal:  Cytokine Growth Factor Rev       Date:  2020-06-20       Impact factor: 7.638

View more
  3 in total

Review 1.  Covalent Reversible Inhibitors of Cysteine Proteases Containing the Nitrile Warhead: Recent Advancement in the Field of Viral and Parasitic Diseases.

Authors:  Simone Brogi; Roberta Ibba; Sara Rossi; Stefania Butini; Vincenzo Calderone; Sandra Gemma; Giuseppe Campiani
Journal:  Molecules       Date:  2022-04-15       Impact factor: 4.927

Review 2.  FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.

Authors:  Aleksandra Sochacka-Ćwikła; Marcin Mączyński; Andrzej Regiec
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

3.  Discovery of new symmetrical and asymmetrical nitrile-containing 1,4-dihydropyridine derivatives as dual kinases and P-glycoprotein inhibitors: synthesis, in vitro assays, and in silico studies.

Authors:  Mohamed H Saad; Tarek F El-Moselhy; Nabaweya S El-Din; Ahmed B M Mehany; Amany Belal; Mohammed A S Abourehab; Haytham O Tawfik; Mervat H El-Hamamsy
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.